Human Complement Component C3a Antibody

Catalog #: MAB3677
3 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB3677
MAB3677-SP

Product Details

Citations (3)

Supplemental Products

Reviews

Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human Complement Component C3a Antibody Summary

Species Reactivity

Human

Specificity

Detects human Complement Component C3a in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) Complement Component C5a or rhComplement Component C3d is observed.

Source

Monoclonal Mouse IgG_2B Clone # 354113

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

E. coli-derived recombinant human Complement Component C3a
Ser672-Arg748
Accession # P01024

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

Recombinant Human Complement Component C3a (Catalog # 3677-C3) under non-reducing conditions only

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Complement Component C3a

C3a is an anaphylotoxin polypeptide comprising amino acids (aa) 672‑748 of the Complement C3 precursor protein (1‑4). Anaphylatoxins are proteolytically generated from the C3, C4 and C5 alpha chains by convertases formed by other complement fragments (2). They share 30‑36% aa identity, and mediate inflammatory responses that vary in strength in the order C5a > C3a > C4a (2). Like C4a and C5a, the 77 aa, 9 kDa human C3a contains six conserved cysteine residues that form a knot structure and possess an overall basic charge (4, 5). It is not glycosylated (4). The C-terminal regions of C3a and C4a, but not C5a, shows antimicrobial activity (5). Human C3a shows 67‑69% aa identity with mouse, rat, guinea pig, bovine, porcine and canine C3a. C3a formation is common to all three pathways of complement activation: classical (antibody-mediated), lectin and alternative (1, 2). It binds the G-protein coupled C3a receptor (C3aR) on myeloid peripheral blood leukocytes, and on activated lymphocytes, endothelial and internal organ epithelial cells (7, 10). C3a contributes to both innate and adaptive immunity. It activates mast cells and neutrophils, triggering robust mast cell degranulation in airways during asthmatic allergen challenges (9). It enhances lipopolysaccharide-induced prostaglandin, cytokine and chemokine secretion by macrophages and other cells (1, 6‑8). It assists in Th2-type inflammatory reactions and stimulates smooth muscle contraction and leukocyte chemotaxis (8, 9). Endogenous carboxypeptidase-N can remove the arginine at the C-terminus of the anaphylatoxins to create desArg forms (1). C3adesArg, also called ASP (Acylation-Stimulating Protein) is an adipocyte-derived protein that binds the C5L2 (GPR77) receptor and stimulates adipose tissue triglyceride synthesis (2, 10, 11). The anaphylactic activity of ASP is weaker than that of C3a (6, 10). C5L2 is also involved in C3a and C5a activity (11).

References

Markiewski, M. and J.D. Lambris (2007) Am. J. Pathol. 171:715.
Haas, P-J. and J. van Strijp (2007) Immunol. Res. 37:161.
DeBruijn, M.H. and G.H. Fey (1985) Proc. Natl. Acad. Sci. USA 82:708.
Hugli, T.E. (1975) J. Biol. Chem. 250:8293.
Pasupuleti, M. et al. (2007) J. Biol. Chem. 282:2520.
Fischer, W.H. et al. (1999) J. Immunol. 162:453.
Thurman, J.M. et al. (2007) J. Immunol. 178:1819.
Honczarenko, M. et al. (2005) J. Immunol. 175:3698.
Ali, H. and R.A. Panettieri (2005) Respir. Res. 6:19.
Kalant, D. et al. (2005) J. Biol. Chem. 280:23936.
Chen, N-J. et al. (2007) Nature 446:203.

Entrez Gene IDs

718 (Human); 12266 (Mouse)

Alternate Names

AHUS5;ARMD9;ASP;C3a;C3b;Complement C3;CPAMD1;HEL-S-62p; Anaphylatoxin; C3; Complement Component C3a

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human Complement Component C3a Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

3 Citations: Showing 1 - 3
Filter your results:

Filter by:

Cryo-EM structures of Trypanosoma brucei gambiense ISG65 with human complement C3 and C3b and their roles in alternative pathway restriction
Authors: H Sülzen, J Began, A Dhillon, S Kereïche, P Pompach, J Votrubova, F Zahedifard, A Šubrtova, M Šafner, M Hubalek, M Thompson, M Zoltner, S Zoll
Nature Communications, 2023-04-27;14(1):2403.
Species: Human
Sample Types: Protein
Applications: Western Blot
Activation of C3a receptor is required in cigarette smoke-mediated emphysema.
Authors: Yuan X, Shan M, You R, Frazier M, Hong M, Wetsel R, Drouin S, Seryshev A, Song L, Cornwell L, Rossen R, Corry D, Kheradmand F
Mucosal Immunol, 2014-12-03;8(4):874-85.
Species: Human
Sample Types: Protein
Applications: Western Blot
Performance characteristics of combinations of host biomarkers to identify women with occult placental malaria: a case-control study from Malawi.
Authors: Conroy AL, Liles WC, Molyneux ME
PLoS ONE, 2011-12-12;6(12):e28540.
Species: Human
Sample Types: Plasma
Applications: ELISA Development